Jaguar Health (JAGX) shares plunged over 64% due to profit-taking following an over 1,100% surge, which was initially triggered by an FDA fee waiver but amplified by low-float volatility after a 1-for-15 reverse stock split. The company faces significant balance sheet pressures, a high cash burn rate, and has signaled an upcoming secondary securities offering, indicating further dilution risks.
Jaguar Health (JAGX) experienced extreme volatility, with shares surging over 1,100% on Tuesday due to an FDA fee waiver for its Mytesi drug, a move significantly amplified by a low public float following a recent reverse stock split. This rally was immediately followed by a sharp 64% decline on Wednesday as investors engaged in profit-taking. The underlying issue for JAGX remains its weak financial position, characterized by a substantial cash burn and significant liabilities, which has led the company to signal a secondary securities offering. This offering, while necessary for capital, poses a significant dilution risk for existing shareholders, overshadowing the modest relief from the FDA fee waiver and suggesting continued downward pressure on the stock in the short to medium term.